Effector Therapeutics Inc (EFTR)

Effector Therapeutics Inc (EFTR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $940; returns 1 day +0.0%.

Effector Therapeutics Inc. (EFTR) was a clinical-stage biopharmaceutical company focused on developing a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's pipeline primarily consisted of two wholly-owned drug candidates: zotatifin, an inhibitor of eukaryotic translation initiation factor 4A (eIF4A), and tomivosertib, a selective MNK inhibitor.

Groups EFTR belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Clinical Stage
• Cancer Therapeutics
• Life Sciences
• Healthcare
• Pharmaceuticals
• Breast Cancer Treatment

EFTR financial model: income statement, cash flow and balance sheet